+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Urokinase type plasminogen activator activity during tumor growth



Urokinase type plasminogen activator activity during tumor growth



Journal of Cancer Research & Clinical Oncology 116(Suppl. Part 1): 183




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034144206

Download citation: RISBibTeXText


Related references

Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis. Journal of Urology 174(2): 461-465, 2005

Urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes are not internalized upon binding to the urokinase-type-plasminogen-activator receptor in THP-1 cells: Interaction of urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes with the cell surface. European Journal of Biochemistry 233(2): 514-519, 1995

Differential effects of acute and chronic wound fluids on urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and tissue-type plasminogen activator in cultured human keratinocytes and fibroblasts. Wound Repair & Regeneration 9(4): 314-322, July-August, 2001

Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease. Annals of Surgical Oncology 10(8): 948-953, 2003

Urokinase-type plasminogen activator , urokinase-type plasminogen activator receptor , plasminogen activator inhibitor type 1 , type 2 , and tissue-type plasminogen activator in breast cancer cells. Fibrinolysis & Proteolysis 14(Suppl. 1): 38, 2000

Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients. Breast Cancer Research & Treatment. 49(1): 41-50,, 1998

Basic fibroblast growth factor, urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in breast cancer cells. Fibrinolysis 10(Suppl. 3): 15, 1996

Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator. Journal of Biological Chemistry 280(17): 17449-17457, 2005

A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor. European Journal of Biochemistry 207(1): 177-183, 1992

Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met. American Journal of Pathology 153(1): 201-212, 1998

Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells. Oncology Reports 17(5): 1259-1268, 2007

Tumor necrosis factor-alpha regulates mRNA for urokinase-type plasminogen activator and type-1 plasminogen activator inhibitor in human neoplastic cell lines. Molecular and Cellular Endocrinology 61(1): 87-96, 1989

Tumor necrosis factor alpha regulates messenger rna for urokinase type plasminogen activator and type 1 plasminogen activator inhibitor in human neoplastic cell lines. Molecular & Cellular Endocrinology 61(1): 87-96, 1989

Tumor necrosis factor and interleukin 1 increase the production of urokinase-type plasminogen activator and of plasminogen activator inhibitor type 1 by human colon carcinoma cells. Experientia 49(ABSTR ): A38, 1993